Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.

The price you pay for Trodelvy may depend on factors such as your dosage and whether you have health insurance. Financial assistance may be available to help you with the cost of Trodelvy.

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into an additional clinical ...

Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate Trodelvy in the treatment of extensive-stage small cell lung cancer ...